ARVO 2025: Nitish Mehta, MD, provides real-world insights from aflibercept 8 mg for treatment-naive diabetic macular oedema
ARVO 2025: Anat Loewenstein, MD, and colleagues on meeting needs of patients with diabetic retinopathy
Prof Loewenstein and a cohort of colleagues assessed the current treatment outlook for patients with diabetic retinopathy
Editorial Advisory Board members bring research findings to ARVO
Members of the Ophthalmology Times Europe, Ophthalmology Times and Modern Retina editorial advisory boards are present and presenting at the 2025 ARVO meeting
ZEISS debuts Research Data Platform, highlights Boehringer Ingelheim partnership
Carl Zeiss Meditec plans to launch the ZEISS RDP in select countries throughout 2025
LuxIA receives CE-MDR certification
LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.
EMA CHMP adopts positive opinion for teprotumumab (Tepezza, Amgen) marketing authorisation application
In the weeks to come, the European Commission will issue a decision on the first severe thyroid eye disease treatment
The future of microbial keratitis treatment is bright
Ultraviolet light’s potential in ocular care extends beyond structural reinforcement to antimicrobial applications, especially for microbial keratitis
Sheng Lim, MD, FRCOphth, brings data from the CONCEPT study to the ASCRS meeting
Endoscopic cyclophotocoagulation (ECP) has major potential for patients with glaucoma
Vision- and life-threatening neuro-ophthalmological presentations
Paediatric diagnoses of juvenile idiopathic intracranial hypertension, optic neuritis and Horner syndrome
Diagnosing types of dry eye in patients with autoimmune disease
ENTOD Pharmaceuticals announces CDSCO approval of 0.05% atropine drops (Myatro XL)
According to a press release, Myatro XL is the first 0.05% atropine eye drop for paediatric myopia control.
Investigating causes of diplopia to minimise morbidity and mortality
Canadian investigators urged quick neuro-ophthalmologic referrals to limit the progress of life- and vision-threatening conditions
Neurotech appoints Beth Marsh as chief commercial officer ahead of US product launch
The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)
New trends in the diagnosis of dry eye disease: A patient-centric approach
A five-step approach to personalise and simplify treatment, leading to higher efficacy
Regeneron announces US FDA complete response letter for aflibercept 8 mg (Eylea HD) supplemental Biologics License Application
The US Food and Drug Administration did not identify any safety or efficacy issues associated with aflibercept 8 mg
Industry updates and clinical trial data at the upcoming 2025 ARVO Annual Meeting
Therapies for retinal vascular disease, dry eye disease, inflammation following glaucoma filtration surgery and more
DMO study meta-analysis illuminates how racial subgroups are underrepresented in clinical trials
The study aimed to clarify how race affects visual outcomes for patients with diabetic macular oedema treated with ranibizumab
Artificial intelligence analyses biomarker changes in neovascular AMD treated with faricimab
The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase
Clinicians may improve follow-up adherence by leveraging social media apps
Social media smartphone application–based interventions significantly improved adherence and parental knowledge among families of children with congenital ectopia lentis
Journal of Neuroinflammation publishes data on Eleva’s lead retinal asset CPV-104
In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease
Alcon marks 110th anniversary of Grieshaber AG site in Switzerland
Alcon acquired the historic ophthalmic instrument company in 2000
Eyestem Research announces positive results from phase 1 geographic atrophy trial
Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting
When will gene therapy be ready for patients with age-related macular degeneration?
Antibody drug discovery company Novelty Nobility joins Johnson & Johnson JLABS Korea
The company's therapeutic candidates include a bispecific antibody to target vascular retinal diseases
"Reel vision syndrome" and short-form videos linked to negative ocular health outcomes
Ophthalmologists report that dry eye syndrome, myopia progression and other ocular pathologies have increased, especially among paediatric patient groups
UK surgeon performs 30,000th laser eye procedure
A pioneer of refractive laser eye surgery in the UK, Professor David Gartry, MD, FRCS, FRCOphth, FCOptom, reached the milestone in the 36th year of his career
Bayer submits EMA application for aflibercept 8 mg third indication, retinal vein occlusion
In the European Union and the United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular oedema
Rethinking race as a risk factor for glaucoma
Social determinants of health challenge our existing expectations
European Commission expands upadacitinib (Rinvoq) indication to include giant cell arteritis
Patients with GCA, an autoimmune disease, are at risk for sudden vision loss which can be permanent
Tenpoint Therapeutics submits US FDA New Drug Application for presbyopia treatment BRIMOCHOL PF
Following Phase 3 pivotal trial BRIO-II, Tenpoint Therapeutics said they hope to launch BRIMOCHOL PF in 2026
